Premium
Urinary leukotriene E 4 levels in patients with atopic dermatitis
Author(s) -
SANSOM J.E.,
TAYLOR G.W.,
DOLLERY C.T.,
ARCHER C.B.
Publication year - 1997
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1046/j.1365-2133.1997.6781625.x
Subject(s) - atopic dermatitis , medicine , dermatology , urinary system , leukotriene c4 , leukotriene e4 , leukotriene , asthma
Summary Leukotriene synthesis may be increased in a variety of inflammatory diseases. Urinary leukotriene E 4 is a stable metabolite of leukotrienes C 4 and D 4 which has previously been found to be increased in exacerbations of severe asthma and after antigen inhalation. Levels of urinary LTE 4 in seven patients during and after a severe flare of atopic dermatitis were measured by high‐performance liquid chromatography (HPLC) and radioimmunoassay (RIA). Mean urinary LTE 4 levels (± SEM) were not increased during (16·7 ± 3·7pg/μmol) or after (16·9 ± 4·8 pg/μxmol) the acute exacerbation of atopic dermatitis when compared with the normal range (mean = 23·8 [95% confidence interval 19·9–28·2] pg/μmol creatinine). These findings do not provide evidence of cysteinyl leukotriene involvement in the pathogenesis of atopic dermatitis.